胃腸道基質腫瘤(GIST) 市場規模、佔有率和成長分析：按療法、藥物、分期、給藥途徑、分銷管道、最終用戶和地區分類－2026-2033 年產業預測

2024 年全球胃腸道間質瘤 (GIST) 市場價值為 13.8 億美元，預計到 2025 年將成長至 14.7 億美元，到 2033 年將成長至 23.8 億美元，在預測期（2026-2033 年）內複合年成長率為 6.2%。

全球胃腸道基質腫瘤(GIST) 市場正經歷強勁成長，主要驅動力是市場對新一代蛋白酪氨酸激酶抑制劑的需求不斷成長，這些抑制劑能夠有效克服第一線治療的抗藥性。隨著接受傳統療法的患者出現抗藥性，轉向二線藥物的趨勢日益明顯，這刺激了製藥業向標靶突變特異性療法的研發創新。聯合治療的引入顯著提高了無惡化存活期，促使企業增加採購投入並擴大庫存。伴隨診斷（用於患者分層）、遠端醫療（用於監測用藥依從性）以及旨在擴大市場佔有率的策略聯盟也蘊藏著巨大的商機。 GIST 診斷數量的激增以及分子譜分析在個人化醫療方面的進步是推動市場發展的關鍵趨勢，加速了從傳統手術治療到標靶治療的轉變。

全球胃腸道基質腫瘤（GIST）市場成長要素

早期診斷日益受到重視，使得醫療專業人員能夠更早地識別胃腸道基質腫瘤，從而擴大了可從根治性治療中獲益的患者範圍。這種積極主動的方法能夠快速啟動標靶治療，改善臨床療效，並激勵臨床醫師採用已核准的治療方案。隨著對診斷指南的認知不斷提高，醫療專業人員擴大將分子檢測納入標準診療流程，這推動了對已通過核准藥物的持續需求，並促進了市場成長。反過來，這一趨勢也促使製藥公司實施教育項目，以推廣這些診斷和治療策略的持續應用。

全球胃腸道間質瘤市場的限制因素

新療法的高成本對胃腸道基質腫瘤治療市場的成長構成重大挑戰。物價上漲限制了病患的就醫途徑，尤其是在報銷保單嚴格或保險覆蓋不足的地區。醫療支付者通常優先考慮成本效益而非臨床療效，導致處方清單受限，處方量減少。此外，醫療機構面臨的財務壓力常常延緩新療法的採用，迫使臨床醫生依賴價格較低廉的傳統療法。因此，儘管創新療法具有潛在的治療益處，但這些經濟障礙阻礙了整體市場需求。

全球胃腸道間質瘤（GIST）市場趨勢

隨著分子譜分析在治療方案選擇中發揮關鍵作用，全球胃腸道基質腫瘤（GIST）市場正經歷著向精準腫瘤學的重大轉變。臨床醫生擴大使用針對個體基因譜客製化的標靶抑制劑，促使製藥公司拓展產品線，不再局限於傳統的蛋白酪氨酸激酶抑制劑。這一趨勢促進了製藥公司與診斷公司建立策略合作夥伴關係，推動了伴隨診斷和符合醫療保險報銷條件的創新治療方案的發展。隨著個人化療法改善患者預後並加速市場普及，全球大學醫院和社區醫療機構的格局正在迅速變化，進一步強化了對個人化癌症治療的重視。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球胃腸道基質腫瘤(GIST) 市場規模：依治療類型分類

• 標靶治療
• 化療
• 免疫療法
• 外科手術
• 放射線治療
• 其他

全球胃腸道基質腫瘤(GIST) 市場規模：依藥物類型分類

• 蛋白酪氨酸激酶抑制劑（TKIs）
• 免疫查核點抑制劑
• 細胞毒性化學療法藥物
• 其他

全球胃腸道基質腫瘤(GIST) 市場規模：依疾病階段分類

• 局限性胃腸道基質腫瘤（GIST）
• 局部進行性胃腸道基質腫瘤（GIST）
• 轉移性胃腸道基質腫瘤（GIST）
• 復發性胃腸道基質腫瘤（GIST）

全球胃腸道基質腫瘤(GIST) 市場規模：依給藥途徑分類

• 口服
• 注射藥物

全球胃腸道基質腫瘤(GIST) 市場規模：依分銷管道分類

• 醫院藥房
• 零售藥房
• 網路藥房

全球胃腸道基質腫瘤(GIST) 市場規模：依最終用戶分類

• 醫院
• 專科癌症中心
• 門診手術中心
• 學術研究機構

全球胃腸道基質腫瘤(GIST) 市場規模：按地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• Novartis AG
• Pfizer Inc
• Bayer AG
• Blueprint Medicines Corporation
• Deciphera Pharmaceuticals Inc
• Bristol Myers Squibb Company
• F Hoffmann-La Roche Ltd
• Merck & Co Inc
• AstraZeneca plc
• Sanofi SA
• Takeda Pharmaceutical Company Limited
• Eli Lilly and Company
• Amgen Inc
• GlaxoSmithKline plc
• Johnson & Johnson Services Inc
• Teva Pharmaceutical Industries Ltd
• Viatris Inc
• Sandoz International GmbH
• Lupin Limited
• Cipla Limited

結論與建議

Global Gastrointestinal Stromal Tumor Market size was valued at USD 1.38 Billion in 2024 and is poised to grow from USD 1.47 Billion in 2025 to USD 2.38 Billion by 2033, growing at a CAGR of 6.2% during the forecast period (2026-2033).

The global gastrointestinal stromal tumor (GIST) market is experiencing robust growth, primarily fueled by the rising demand for next-generation tyrosine kinase inhibitors that effectively address resistance to first-line treatments. As patients on conventional therapies develop resistance, there is a notable shift towards second-line drugs, which has invigorated pharmaceutical innovation in developing targeted, mutation-specific therapies. The integration of combination regimens has significantly enhanced progression-free survival rates, prompting increased investment in procurement and inventory expansion. Key opportunities also lie in companion diagnostics for patient stratification, telemedicine for monitoring adherence, and strategic partnerships aimed at expanding market presence. The surge in GIST diagnoses and advancements in molecular profiling for personalized treatments are pivotal trends propelling the market forward, facilitating a transition towards targeted therapies over traditional surgical options.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Gastrointestinal Stromal Tumor market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Gastrointestinal Stromal Tumor Market Segments Analysis

Global gastrointestinal stromal tumor market is segmented by treatment type, drug type, disease stage, route of administration, distribution channel, end user and region. Based on treatment type, the market is segmented into targeted therapy, chemotherapy, immunotherapy, surgery, radiation therapy and others. Based on drug type, the market is segmented into tyrosine kinase inhibitors (TKIs), immune checkpoint inhibitors, cytotoxic chemotherapy agents and others. Based on disease stage, the market is segmented into localized gastrointestinal stromal tumor (GIST), locally advanced gastrointestinal stromal tumor (GIST), metastatic gastrointestinal stromal tumor (GIST) and recurrent gastrointestinal stromal tumor (GIST). Based on route of administration, the market is segmented into oral and injectable. Based on distribution channel, the market is segmented into hospital pharmacies, retail pharmacies and online pharmacies. Based on end user, the market is segmented into hospitals, specialty cancer centers, ambulatory surgical centers and academic & research institutes. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Gastrointestinal Stromal Tumor Market

The growing focus on early diagnosis is enabling healthcare professionals to identify gastrointestinal stromal tumors at earlier stages, thus broadening the range of patients who can benefit from curative treatments. This proactive approach facilitates the prompt initiation of targeted therapies, enhancing clinical outcomes and motivating clinicians to utilize approved treatment options. As awareness of diagnostic guidelines rises, healthcare providers are increasingly incorporating molecular testing into their standard practices, which fuels persistent demand for approved medications and contributes to market growth. In turn, this trend encourages pharmaceutical companies to implement educational initiatives that promote the ongoing adoption of these diagnostic and treatment strategies.

Restraints in the Global Gastrointestinal Stromal Tumor Market

The high cost associated with new therapies presents a significant challenge to the growth of the gastrointestinal stromal tumor treatment market. Elevated prices restrict patient access, particularly in regions with stringent reimbursement policies or insufficient insurance coverage. Healthcare payers often prioritize cost-effectiveness over clinical benefits, leading to restrictive formularies that diminish prescription volumes. Additionally, financial pressures faced by healthcare institutions frequently result in delays in adopting newer treatments, causing clinicians to rely on older, more affordable options. Consequently, these financial barriers hinder overall market demand, despite the potential therapeutic advantages offered by innovative treatments.

Market Trends of the Global Gastrointestinal Stromal Tumor Market

The Global Gastrointestinal Stromal Tumor (GIST) market is experiencing a notable shift towards precision oncology, as the integration of molecular profiling becomes integral to therapy selection. Clinicians are increasingly utilizing targeted inhibitors tailored to individual genetic profiles, prompting pharmaceutical companies to diversify their pipelines beyond conventional tyrosine kinase inhibitors. This trend fosters strategic partnerships with diagnostic firms, enhancing the development of companion diagnostics and innovative treatment bundles that are eligible for reimbursement. As personalized regimens improve patient outcomes and drive market adoption, the landscape is evolving rapidly across academic and community healthcare settings worldwide, reinforcing the commitment to individualized cancer care.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Gastrointestinal Stromal Tumor Market Size by Treatment Type & CAGR (2026-2033)

• Market Overview
• Targeted Therapy
• Chemotherapy
• Immunotherapy
• Surgery
• Radiation Therapy
• Others

Global Gastrointestinal Stromal Tumor Market Size by Drug Type & CAGR (2026-2033)

• Market Overview
• Tyrosine Kinase Inhibitors (TKIs)
• Immune Checkpoint Inhibitors
• Cytotoxic Chemotherapy Agents
• Others

Global Gastrointestinal Stromal Tumor Market Size by Disease Stage & CAGR (2026-2033)

• Market Overview
• Localized Gastrointestinal Stromal Tumor (GIST)
• Locally Advanced Gastrointestinal Stromal Tumor (GIST)
• Metastatic Gastrointestinal Stromal Tumor (GIST)
• Recurrent Gastrointestinal Stromal Tumor (GIST)

Global Gastrointestinal Stromal Tumor Market Size by Route of Administration & CAGR (2026-2033)

• Market Overview
• Oral
• Injectable

Global Gastrointestinal Stromal Tumor Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Gastrointestinal Stromal Tumor Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Specialty Cancer Centers
• Ambulatory Surgical Centers
• Academic & Research Institutes

Global Gastrointestinal Stromal Tumor Market Size & CAGR (2026-2033)

• North America (Treatment Type, Drug Type, Disease Stage, Route of Administration, Distribution Channel, End User)
  • US
  • Canada
• Europe (Treatment Type, Drug Type, Disease Stage, Route of Administration, Distribution Channel, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Treatment Type, Drug Type, Disease Stage, Route of Administration, Distribution Channel, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Treatment Type, Drug Type, Disease Stage, Route of Administration, Distribution Channel, End User)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Treatment Type, Drug Type, Disease Stage, Route of Administration, Distribution Channel, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Blueprint Medicines Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Deciphera Pharmaceuticals Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F Hoffmann-La Roche Ltd
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi SA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson Services Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Viatris Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sandoz International GmbH
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lupin Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations